TScan Therapeutics, Inc.TScan Therapeutics, Inc.TScan Therapeutics, Inc.

TScan Therapeutics, Inc.

No trades
See on Supercharts

TCRX fundamentals

An in-depth look to TScan Therapeutics, Inc. operating, investing, and financing activities

TCRX free cash flow for Q3 24 is -29.29 M USD. For 2023, TCRX free cash flow was -64.5 M USD and operating cash flow was -61.36 M USD.

Q1 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q1 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
TTM
Free cash flowYoY growth